Pseudoprogression as an adverse event of glioblastoma therapy
Open Access
- 3 November 2017
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 6 (12) , 2858-2866
Abstract
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression‐free survival (PFS), post‐progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5‐fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606–7.564; P = 0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3 months; P = 0.0001) but was similar for PsP and nP patients (P = 0.91). OS was shorter–though not significantly so—for PsP than nP patients (OS: 19.5 vs. 27.9 months; P = 0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P = 0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P = 0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.Keywords
Funding Information
- Fundació la Marató TV3 (665/C/2013)
- citizens’ initiative “Montgat en Acció”
This publication has 36 references indexed in Scilit:
- Irradiated Volume as a Predictor of Brain Radionecrosis After Linear Accelerator Stereotactic RadiosurgeryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Pseudoprogression Following Chemoradiotherapy for Glioblastoma MultiformeCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2010
- Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBMCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2009
- Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomideCancer, 2008
- Clinical features, mechanisms, and management of pseudoprogression in malignant gliomasThe Lancet Oncology, 2008
- MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma PatientsJournal of Clinical Oncology, 2008
- Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastomaJournal of Neuro-Oncology, 2006
- Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Selection of Eligible Patients with Supratentorial Glioblastoma Multiforme for Gross Total ResectionJournal of Neuro-Oncology, 2001